Drugs in development for herpes simplex and varicella zoster virus

The alpha‐herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard‐of‐care (SoC) is based on nucleoside analogs (NAs), which require specific activatio...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2017-07, Vol.102 (1), p.30-32
Main Authors: Birkmann, A, Zimmermann, H
Format: Article
Language:English
Subjects:
Antiviral Agents - classification
Antiviral Agents - pharmacology
DNA Helicases - antagonists & inhibitors
DNA Primase - antagonists & inhibitors
Herpes Simplex - drug therapy
Herpes Simplex - virology
Herpes Zoster - drug therapy
Herpes Zoster - virology
Herpesvirus 3, Human - drug effects
Herpesvirus 3, Human - physiology
Humans
Medication Therapy Management - trends
Nucleosides - pharmacology
Simplexvirus - drug effects
Simplexvirus - physiology
Viral Proteins - antagonists & inhibitors
Virus Replication - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The alpha‐herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard‐of‐care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.647